TLR7 agonism accelerates disease in a mouse model of primary Sjögren’s syndrome and drives expansion of T-bet+ B cells

• Published in: Frontiers in immunology Vol. 13; p. 1034336
• Main Authors: Punnanitinont, Achamaporn, Kasperek, Eileen M., Kiripolsky, Jeremy, Zhu, Chengsong, Miecznikowski, Jeffrey C., Kramer, Jill M.
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 15.12.2022
• Subjects: ABC; Adjuvants, Immunologic - pharmacology; age-associated B cells; Animals; autoantibodies; autoimmunity; B-Lymphocytes - drug effects; B-Lymphocytes - immunology; Female; Imiquimod - pharmacology; Immunology; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Myeloid Differentiation Factor 88 - genetics; Myeloid Differentiation Factor 88 - immunology; NOD.B10; sialadenitis; Sjogren's Syndrome - genetics; Sjogren's Syndrome - immunology; Toll-Like Receptor 7 - agonists; Toll-Like Receptor 7 - genetics; Toll-Like Receptor 7 - immunology; ABC; autoimmunity; sialadenitis; autoantibodies; age-associated B cells; NOD.B10

Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease characterized by chronic inflammation of exocrine tissue, resulting in loss of tears and saliva. Patients also experience many extra-glandular disease manifestations. Treatment for pSS is palliative, and there are currently no treatme...